Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 10, 2019
Veltassa® (patiromer) enables spironolactone for blood pressure management in patients with resistant hypertension and chronic kidney disease by controlling blood potassium levels. ZURICH, 10 May...
-
May 8, 2019
Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Dr. Sue Mahony and Kim Stratton and to the Board of Directors Confirmation of all members...
-
Apr 25, 2019New vial options deliver on CSL Behring’s heritage of innovation by providing more alternatives to patients
25 Apr 2019 KING OF PRUSSIA, Pa. – 25 April 2019 – Global biotherapeutics leader CSL Behring today announced that the US Food and Drug Administration (FDA) has approved 4- and 5-gram vial...
-
Apr 11, 2019
Agreement to jointly commercialise the new diabetic kidney disease (DKD) indication for INVOKANA® (canagliflozin) in the US Only diabetes treatment indicated to slow down the progression of DKD...
-
Apr 9, 2019Leading global biotech company brings innovative therapies for life-threatening medical conditions to UAE
Dubai, UAE - 9 April, 2019 – CSL Behring, a global biotherapeutics leader, has inaugurated its regional headquarters at Dubai Science Park (DSP), a holistic science-focused business community...